400
Participants
Start Date
December 16, 2020
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Pembrolizumab
Administered via IV infusion at a dose of 400 mg Q6W
Favezelimab/Pembrolizumab
Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Belzutifan
Administered via oral tablet at a dose of 120 mg QD
Lenvatinib
Administered via oral capsule at a dose of 20 mg QD
Pembrolizumab/Quavonlimab
Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Vibostolimab/Pembrolizumab
Administered via IV infusion at a dose of 200 mg/200 mg Q6W
Auckland City Hospital ( Site 1700), Auckland
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 2301), Budapest
Western Sydney Local Health District ( Site 1601), Blacktown
St George Hospital ( Site 1602), Kogarah
Austin Health ( Site 1600), Heidelberg
Royal Brisbane and Women s Hospital ( Site 1603), Herston
Laura and Isaac Perlmutter Cancer Center ( Site 1016), New York
Memorial Sloan Kettering Cancer Center ( Site 1002), New York
UPMC Cancer Center/Hillman Cancer Center ( Site 1017), Pittsburgh
Duke Cancer Institute ( Site 1015), Durham
Hospital Universitario Ramon y Cajal ( Site 1301), Madrid
Institut Claudius Regaud ( Site 1200), Toulouse
Henry Ford Health System ( Site 1014), Detroit
University of Iowa ( Site 1012), Iowa City
Sheba Medical Center - Oncology Division ( Site 1501), Ramat Gan
Institut De Cancerologie De Lorraine ( Site 1204), Vandœuvre-lès-Nancy
University of Chicago ( Site 1013), Chicago
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1203), Strasbourg
UTSW Medical Center ( Site 1003), Dallas
University of California at San Francisco ( Site 1008), San Francisco
Gustave Roussy ( Site 1202), Villejuif
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1900), Bogotá
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1905), Valledupar
Oncomédica S.A.S ( Site 1904), Montería
Fundación Valle del Lili ( Site 1901), Santiago de Cali
ONCOCENTRO APYS-ACEREY ( Site 2103), Viña del Mar
Rambam MC ( Site 1500), Haifa
James Lind Centro de Investigación del Cáncer ( Site 2108), Temuco
CIDO SpA-Oncology ( Site 2106), Temuco
Rabin Medical Center ( Site 1502), Petah Tikva
Sourasky Medical Center ( Site 1503), Tel Aviv
FALP-UIDO ( Site 2100), Santiago
Oncovida ( Site 2107), Santiago
Bradfordhill-Clinical Area ( Site 2101), Santiago
Hadassah Medical Center-Oncology ( Site 1504), Jerusalem
Yale-New Haven Hospital-Yale Cancer Center ( Site 1011), New Haven
Princess Margaret Cancer Centre ( Site 1101), Toronto
Jewish General Hospital ( Site 1100), Montreal
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402), Amsterdam
Erasmus Medisch Centrum ( Site 2401), Rotterdam
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2201), Bydgoszcz
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 2200, Warsaw
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2202), Gdansk
Asan Medical Center ( Site 1800), Songpagu
Severance Hospital ( Site 1802), Seoul
Samsung Medical Center ( Site 1801), Seoul
Hospital Universitari Vall d Hebron ( Site 1300), Barcelona
Southampton General Hospital ( Site 1403), Southampton
The Beatson West of Scotland Cancer Centre ( Site 1405), Glasgow
Royal Preston Hospital ( Site 1406), Preston
Leicester Royal Infirmary ( Site 1408), Leicester
Barts Health NHS Trust ( Site 1401), London
Western General Hospital ( Site 1402), Edinburgh
Velindre Cancer Centre Hospital ( Site 1407), Cardiff
The Christie NHS Foundation Trust ( Site 1400), Manchester
Merck Sharp & Dohme LLC
INDUSTRY